Record FY26 sales revenue of $23.9m, up 30% year-over-year, with Biome Daily leading Australian pharmacy probiotics. Q4 saw strong cash inflow, reduced debt, and expansion of clinical trials, while onshore manufacturing is set to boost efficiency in FY27.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.